The first domestic combination of nurulimab + prolgolimab: from clinical development and economic analysis to real-world use in disseminated melanoma

Authors:

Abstract
Immunotherapy with immune checkpoint inhibitors has dramatically shifted the prognosis for outcomes of melanoma treatment. However, enhancing the efficacy of dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 while reducing immune-mediated toxicity remains a clinically significant challenge. This article presents a systematic review of data on the first homegrown fixed-dose combination of dual immune checkpoint inhibitors: anti-CTLA-4 + anti-PD-1 (Nurulimab) + Prolgolimab (Nurdati, BCD-217). We searched articles in the PubMed/MEDLINE, eLIBRARY.ru, ClinicalTrials.gov , Cochrane Library databases, and specialized oncology congress records, using the following keywords in different combinations: unresectable/metastatic melanoma, immunotherapy, checkpoint inhibitors, nurulimab, prolgolimab, Nurdati. A total of 146 articles and information sources were identified at the first stage. After removing duplicates and materials irrelevant to the review topic, 118 records were selected for screening, of which 54 were included in the qualitative analysis. The final review included articles and records covering the molecular and pharmacological properties of nurulimab and prolgolimab, the results of the BCD-217 clinical development, comparative efficacy and safety data, and a cost-effectiveness analysis. The excluded articles got the following reasons in favour of exclusion: inappropriateness, lack of clinical data, duplicate results, and limited access to the full text. In the randomized phase III OCTAVA study, the combination of nurulimab plus prolgolimab demonstrated significantly superior efficacy over prolgolimab monotherapy in terms of median progression-free survival (PFS) with comparable cumulative incidence rates of grade 3–4 AEs. Nurdati is a homegrown innovative medicine that is based on a low-dose CTLA-4 blockade and standard anti-PD-1 therapy, demonstrating durable disease control in a patient with BRAF-wild-type acral melanoma in the presented clinical case.

This publication has 24 references indexed in Scilit: